Skip to main content
Premium Trial:

Request an Annual Quote

ArQule Will Use System Built With SignalGene for Its Own p38 Goals

NEW YORK, Feb. 21 - ArQule will apply the computational compound design system it co-designed with SignalGene to its own p38 MAP kinase drug-discovery program, the two companies said on Thursday.


The firms agreed in January 2001 to develop this system, and as part of that agreement will now apply it to design, generate, and evaluate new compounds that target p38 MAP kinase.


ArQule will produce the new compounds and test them for biological activity. The company has development rights to these compounds.


SignalGene, in return, will receive research fees and milestone payments for any relevant new compounds.


The system that the two companies developed employs interaction data and 3-D structure knowledge in order to come up with new drugs.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.